Thema: KYG549581067
Hansoh Pharma, KYG549581067
stock-5275746_1920(1).jpg - Foto: THN
Hansoh Pharma stock: Phase 3 data strengthen oncology pipeline
Hansoh Pharma stock is in focus after positive Phase 3 osteosarcoma data for its ADC candidate Ris-Rez. The study met its primary endpoint.
ad-hoc-news.de, heute 02:11 Uhr
Hansoh Pharma, KYG549581067
Hansoh Pharma Stock Draws HKD 47.73 Target From 24 Analysts ...
Hansoh Pharma trades at 24.60 times earnings versus a 16.60 peer average. Hansoh Pharma stock costs EUR 3.89 on October 20, 2026 at 7:39 p.m. CEST.
ad-hoc-news.de, 20.10.26 19:45 Uhr
Hansoh Pharma, KYG549581067
Hansoh Pharma stock gets HKD 47.82 consensus target
First-half revenue reached CNY 8.30 billion. Hansoh Pharma stock stood at HKD 31.74 on October 16, 2026, up 1.15 percent on HKEX.
ad-hoc-news.de, 17.10.26 21:55 Uhr
Hansoh Pharma, KYG549581067
Hansoh Pharma reports 11.71 percent revenue growth for Hansoh ...
First-half profit rose 35.82 percent on August 26, 2026. Hansoh Pharma stock costs EUR 3.54 on October 15, 2026, up 2.62 percent on the Hong Kong Stock Exchange.
ad-hoc-news.de, 15.10.26 21:32 Uhr
Hansoh Pharma, KYG549581067
Hansoh Pharma presents phase 2b data: what it means for ...
The study randomized 363 patients and supports a phase 3 move. For Hansoh Pharma stock, this adds 19.30 percent weight loss from phase III data.
ad-hoc-news.de, 13.10.26 03:28 Uhr
Hansoh Pharma, KYG549581067
Hansoh Pharma stock fell 1.97 percent to HKD 33.92
Hansoh Pharma stock posted RMB 4.258 billion in first-half profit on August 26, 2026, up 35.82 percent year over year. The shares were last at HKD 33.92 on October 7.
ad-hoc-news.de, 08.10.26 02:44 Uhr
Hansoh Pharma, KYG549581067
Hansoh Pharma stock weighs pipeline gains against EU setback ...
